Abstract. Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a "mutatomics" screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8% of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential.
Mutations and cancer
Mutations leading to the deregulation of critical genes are thought to underlie the multi-step process contributing to cancer development [33] . These may involve activating mutations in proto-oncogenes (e.g. EGFR, BRAF), and/or inactivating mutations in tumor suppressor (e.g. RB1, APC) and "caretaker genes" (e.g. BRCA1, MSH2). DNA sequence analysis of such genes offers both opportunities for diagnosing cancer predisposition, for somatic cancer diagnosis, and for targeting therapeutics towards tumors with specific, clonally selected genetic alterations. Only roughly 1% of genes are known to harbor mutations in cancer [8] and only a handful of these are relevant to the diagnosis or therapeutic management of common solid tumors, such as the common epithelial cancers. Finding new mutated genes is slow and labor-intensive, even in the genomic era. For example, there are dozens if not hundreds of specific sites for deletions and allelic losses along chromosomal arms, but very few of these have yet been associated with mutated tumor suppressor genes. Therefore, more effective methods to identify genes with DNA sequence alterations are needed. We, among several other groups, have recently illustrated the potential of the nonsense-mediated mRNA decay (NMD) microarray strategy in highlighting putative mutated genes in cancer [11, 13, 29] .
Nonsense-mediated mRNA decay (NMD)
The NMD-pathway is evolutionarily well-conserved and functions to protect cells from the deleterious ef-fects of mutations and errors in the transcription leading to premature termination codons (PTCs) [4, 21] . Accumulation of truncated proteins could act in a dominant-negative manner or otherwise interfere with normal cellular functions. It has been estimated that about one third of the mutations associated with human diseases are nonsense mutations that result in PTCs [10, 23] .
In eukaryotes, messenger RNAs containing nonsense mutations are selectively and rapidly degraded by the NMD-pathway during translation [21, 24] . In mammalian cells, NMD is linked to splicing and involves the formation of exon-junction-complex (EJC) 20-24 nucleotides 5 of each exon-exon junction [2, 17] . EJC acts together with a group of Upf proteins to trigger the formation of a multi-protein surveillance complex after splicing [22] . The complexes are normally displaced from the mRNA by the first translating ribosome. In case of a PTC, at least one of the surveillance complexes remains bound to the mRNA, leading to phosphorylation of UPF1/RENT1 and activation of the NMD machinery [5, 35] , details of which remain partly unknown. In order to elicit NMD, the PTC must lie more than 50 to 55 nucleotides upstream of the last exon-exon junction [3, 28] . In addition, close proximity of PTC to the translation initiation codon has been postulated to interfere with the activation of NMD [12] . Activation of NMD results in rapid transcript degradation through deadenylation of the poly(A) tail followed by 3 -5 degradation, and/or decapping of the mRNA followed by 5 -3 degradation [18, 31] . Most PTC containing mRNAs are subject to nucleusassociated NMD, whereas minority of NMD driven mRNA degradation occurs in the cytoplasm [25] .
Recent views suggest that instead of acting merely as a quality control mechanism, NMD may function primarily as a regulator of physiological transcripts. Such physiologic substrates for NMD have been shown to include transcripts with alternative splice forms that introduce nonsense codons or frameshift mutations to the spliced sequence, open reading frames in the 5 untranslated region and introns in the 3 untranslated region [7, 20, 26, 30, 34] . NMD regulated transcripts have been shown to include particularly those involved in amino acid metabolism, immune maturation, telomere capping, embryonic development, as well as those encoding selenoproteins [19, 26, 27] .
Manipulation of the NMD pathway for mutation screening
Noensie and Dietz initially proposed the "GINI" (Gene Identification by NMD Inhibition) technology for the discovery of mutations without any a priori information on the disease or the genes of interest [29] . In this method, the NMD pathway is blocked pharmacologically by treating the cells with a translational inhibitor, such as emetine, or by siRNAs against Rent1 [26, 29] , a key protein involved in the NMD process. As a consequence of such treatment, mutated transcripts containing PTCs are stabilized and accumulate in the cells during culture. The corresponding enrichment in mRNA abundance can be monitored by comparing mRNA levels before and after treatment using standard gene expression microarrays. This makes it possible to identify transcripts that are stabilized by the NMD inhibition.
The use of translation inhibitors, such as emetine, prolongs the half-lives of numerous mRNAs, not just those having PTCs, introducing "noise" to the data [32] . Bioinformatic analysis of the inhibition data, along with data from untreated cells, should therefore be used to facilitate distinction of transcripts with truncating mutations from physiologic substrates for NMD ("genomic noise") as well as transcripts that are otherwise stabilized or up-regulated by the drug or siRNA treatment. Several methods can be used to filter out nonPTC containing emetine induced transcripts. One approach is to assume any given gene is mutated in only a fraction of samples. Genes induced in more than one or two cell lines can then be excluded as likely physiological NMD substrates or as genes that are transcriptionally induced by emetine. Normal cell lines would be especially informative, since they are not expected to contain PTC mutations. In practice, comparison of our unpublished results to those of Ionov and colleagues [13] has shown that a significant fraction of emetine induced genes are the same in different cell lines. Emetine induced genes can also be excluded if they contain specific sequence features, such as 5 open reading frames or 3 introns, which are found in physiological NMD substrates.
In the context of a large international consortium, we recently applied the NMD technique to screen for mutated transcripts in prostate cancer cell lines [11] . Studies of chromosomal deletions in tumor tissues and cell lines have identified dozens of specific genomic regions that may harbor yet to be identified tumor-suppressor genes important for prostate cancer progression [6] . These altered regions contain, however, hundreds of candidate genes making the positional discovery of disease-causing mutations a challenging effort. As bi-allelic inactivation of tumor suppressor genes often involves deletion of the wild-type allele in addition to mutation of the other allele [15] , we integrated the NMD microarray data with comparative genomic hybridization (CGH) microarray data. This makes it possible to focus the search of putative mutated tumor suppressor genes to the deleted chromosomal regions of the cancer cells as visualized by high-resolution CGH microarray data. Figure 1 shows a schematic overview of the NMD microarray-based analysis for mutation detection.
Application of this integrated NMD-CGH method led to the ∼1000-fold enrichment of known TSG mutations in the analyzed cancer cell lines, and to the discovery of a new tumor suppressor candidate, EPHB2, which is mutated in 8% of patient samples from ad-vanced and metastatic prostate cancers. Furthermore, reconstitution of the wild-type EPHB2 in the DU 145 prostate cancer cells suppressed clonogenic growth, providing functional evidence of the tumor suppressing properties of this gene [11] . EPHB2 belongs to the largest family of receptor tyrosine kinases that are involved in cell-to-cell communication. EPHB2 has been postulated to control positioning of proliferative and differentiated cells in normal tissues, such as in the colorectal crypts [1, 9, 16] . EPHB2 may therefore be a critical gene whose loss explains the dysregulation of tissue architecture, one of the hallmarks of cancer.
Cancer cell lines manifesting microsatellite instability (MSI) are prone to accumulate mutations, especially frameshifts leading to downstream stop codons at numerous sites in the genome. Ionov and collaborators reported the application of the NMD microarray analysis in colorectal cancer cell lines with MSI [13, 14] . In addition to emetine, cells were treated simultaneously with actinomycin D, a transcription inhibitor, to prevent new transcription and, as a result, minimizing the effect of emetine-based stress response [13] . Using this strategy, candidate mutated genes were identified. Sequence alterations were verified in genes encoding UVRAG and p300, the first having a putative role in DNA repair process and the latter, functioning as a histone acyltransferase, with a regulatory effect on p53 activity [14] .
Future prospects
Manipulating the NMD-pathway, followed by microarray analyses has already been applied in various discovery approaches for mutated genes. The first published studies [11, 13, 26, 29] illustrate the potential of this approach as a research tool. Typically, each NMD analysis creates a long list of candidate genes to study, including many false positive hits. Several hits may reflect alternatively spliced gene products, that may be informative on their own, rather than nonsense transcripts with genomic mutations. Many versions of the NMD microarray technology have been created, including incubations with emetine only, emetine together with or followed by actinomycin D, as well as RNA interference treatment to silence a key NMD component, such as Rent1. We have advocated the integration with CGH array data as well as kinetic assays to determine transcript decay rates, and to increase the signal relative to noise. The optimal method to achieve detection of transcript decay rates remains to be determined. In our previous study [11] , actinomycin D treatment was applied to stop transcription of the cancer cells, thereby allowing changes in decay rates to be better defined. We have recently observed (unpublished data of the authors) that the application of actinomycin D after emetine incubation does not have a significant effect on the treated cells, suggesting that this combination of the two drugs may not work as well as initially suggested. This is most likely due to the non-specific stabilization of the transcriptome, which has been suggested to be induced by most translational inhibitors (such as emetine), thereby protecting the transcripts from the degradation machinery [32] . Therefore, rather than using the chemical translation inhibitors, RNAi-based knockdown of specific components of the NMD machinery may be more informative.
It is important to note that the NMD-based methods are research tools for cancer gene discovery and are applied in cancer cell lines grown in vitro, not for human tumor diagnosis. It is generally known that such in vitro growing cancer cell lines contain additional genetic alterations unrelated to tumorigenesis, making verification of the initial findings in patient samples crucial in the molecular pathology laboratories. In the future, it may be possible to optimize the method for studying patient samples, such as lymphoblastoid cell lines from patients with hereditary cancer, or in primary cultures of cancer cells (such as leukemias).
In summary, microarray-based NMD inhibition survey holds great potential as a rapid discovery tool for identifying nonsense-mutated transcripts in a wholegenome screening assay, but the optimal strategy for NMD manipulation remains to be determined.
